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however, some patients experience side-effects and develop statin-associated symptoms (SAS). 2 • SAS can include muscle-related symptoms (MRS), which lead to discontinuation of therapy in 5-20% of patients; other side-effects occur in 1-2% of patients (e.g., gastric symptoms, persistent elevation in transaminases). 3, 4 • In 2014, we conducted a web-based survey to understand how clinicians identify and manage patients with SAS in clinical practice. At the time of the study, clinical guidelines did not provide detailed criteria for the diagnosis of SAS. A consensus statement on this topic has since been published by the European Atherosclerosis Society.
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OBJECTIVE
• In this analysis, we compared results from European participants in our survey with published guidelines, to assess how real-world practice aligns with the latest clinical consensus.
METHODS
• The European component of this web-based survey included clinicians in France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, and the UK. The survey was conducted in February-March 2014.
• Sixty clinicians were recruited in each country, with pre-specified quotas to ensure representation from different regions. Two-thirds of clinicians were specialists consultants (from here on referred to as specialists) and the remaining third were general/family physicians (GPs).
• All clinicians were required to have:
• at least 2 years' experience in their current clinical role • treated at least 75 patients (specialists) or 50 patients (GPs) with hypercholesterolemia in the previous 12 months • treated at least 5 patients with SAS in the previous 12 months.
• All participants provided informed consent.
• Ethics approval was obtained from the Human Research Ethics Committee of the University of Technology, Sydney, Australia.
• The survey was developed in collaboration with clinical advisors, and included questions about diagnostic criteria, the estimated number of patients diagnosed with SAS, and clinicians' choice of treatment for patients with SAS, based on their clinical experience.
• The methodology for developing the questionnaire and conducting the survey is summarized in Table 1 
RESULTS
Participant demographics
• A total of 480 clinicians (161 GPs and 319 specialists) from Europe completed the survey; 76% of the specialists were cardiologists, 19% endocrinologists, and 5% lipidologists.
Identification of patients with SAS
Signs or symptoms that might be associated with SAS • Considering their patients who had been newly-prescribed statins, almost all clinicians (average 98%) reported seeing patients with MRS potentially associated with statins ( Figure 1 ). Clinical criteria used to establish SAS
Figure 1 Proportion of clinicians who reported observing MRS that may indicate SAS in patients prescribed statins
• Across countries, an average of 52% of clinicians reported testing in patients who displayed symptoms that suggested SAS (Figure 2 ). There was considerable variation between countries as to whether patients were tested as routine practice: an average of 53% of clinicians reported testing routinely in all patients and 16% in some patients. Upon symptoms Routine practice in all patients Routine practice in some patients
Respondents could select from "upon symptoms", "routine practice -some patients" and "routine practice -all patients". Multiple options could be selected; consequently, percentages for routine practice, which adds together the "some" and "all" categories, may exceed 100%.
• On average, 77% of clinicians (range 68-85%) reported trying ≥2 statins before considering MRS to be SAS; 65% of clinicians (range 57-73%) tried ≥3 statins ( Figure 3 ). • An average of 61% of clinicians (range 50-67%) reported discontinuing the statin to test whether MRS resolved.
• Overall, an average of 38% of clinicians (range 32-45%) reported using a combination of rechallenging, discontinuing, and lowering the dose of statin to confirm SAS.
• A small number of clinicians (15, 3%) selected none of these three options as part of their minimum criteria for establishing SAS.
• The majority of clinicians (average of 82%; range 73-89%) require known elevated CK levels to decrease after modifying or stopping a statin in order to establish SAS ( Figure 5 ). 
82% 9% 9%
• The study was not statistically powered for epidemiology analysis or interpretation; however, we estimated that an average of 5% (range 2-11%) of patients with hypercholesterolemia treated with statins have confirmed SAS (Figure 6 ), based on the criteria of individual clinicians. (Table 2) , although the results regarding the use of routine CK testing and the use of low/intermittent dose regimens are not fully consistent.
Table 2 Comparison of EASCPS recommendations and survey findings
EASCPS recommendations for identifying SAS in patients with MRS
Survey findings
Assessment of the probability of SAMS being due to a statin should take account of:
• the nature of the muscle symptoms • the elevation of CK levels • the temporal association with statin initiation, discontinuation, and rechallenge.
The majority of clinicians examine the temporal association of MRS and CK elevation through rechallenge in patients with suspected SAS.
Routine CK monitoring is not recommended (given the rarity of elevation, and that the clinical significance of asymptomatic elevations is unclear).
Routine CK monitoring of all patients newly prescribed statins is common in some countries.
Management should take into account the degree of any elevation in CK:
• Patients with MRS and normal/mild/ moderate elevation of CK (majority) -withdrawal of statin therapy followed by rechallenge can help determine causality.
• Patients with MRS and CK elevation >4 × upper limit of normal (minority) -statin should be stopped; if statin is considered important given a patient's CVD risk, a lower-dose statin regimen can be continued with monitoring.
• In addition to use of routine monitoring, 52% of clinicians would test CK levels upon presentation of MRS.
• Testing of association of symptoms by rechallenge was required by 74% of clinicians.
Additional approaches to continuing statin therapy include use of:
• a second alternative statin • a third efficacious statin at a low dose • intermittent (non-daily) dosing.
• An average of 77% and 65% of clinicians tried ≥2 and ≥3 statins, respectively. • Testing of lower-dose and intermittentdose statin regimens was less commonly required in all countries.
CONCLUSIONS
• Our survey establishes that clinicians are familiar with SAS; however, in the absence of clear clinical guidance, they developed individual practices to identify affected patients.
• The reported clinical criteria used to identify patients with SAS across eight European countries are broadly consistent with the current clinical consensus in Europe. 5 • Based on clinicians' responses and individual criteria for diagnosis, the estimated proportion of patients with SAS in this study (average 5%) is consistent with the range of 5-10% reported in literature. 
